Research programme: neurodegenerative disease therapeutics - VECT-HORUS/Sanofi

Drug Profile

Research programme: neurodegenerative disease therapeutics - VECT-HORUS/Sanofi

Alternative Names: Peptide vectors - VECT-HORUS; Peptide-vector-antibody conjugates

Latest Information Update: 15 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi
  • Developer Sanofi; VECT-HORUS
  • Class Antibodies; Drug conjugates; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurodegenerative disorders

Most Recent Events

  • 19 Jan 2015 Sanofi in-licenses VECT-HORUS’s proprietary technology for peptide-vectors VECT-HORUS
  • 19 Jan 2015 Early research in Neurodegenerative disorders in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top